Social Anxiety Disorder (SAD) , also known as social phobia, is a debilitating condition characterised by intense, persistent fear of being scrutinised and negatively evaluated in social situations. Unlike temporary nervousness, this disorder causes significant functional impairment, with a lifetime prevalence reaching up to 12%. Typical age of onset is early adolescence (around 13 years), yet individuals often suffer for 15–20 years before seeking help, mistaking symptoms for shyness.
Diagnostic Framework (DSM-5)
Symptoms must persist for ≥6 months and cause clinically significant distress or impairment. Core fear involves social situations in which the individual fears acting in a way that will be humiliating or lead to rejection. The fear is out of proportion to the actual threat.
Clinical Manifestations
Physical symptoms include blushing (a hallmark response), palpitations, sweating, trembling, dry mouth, and “shy bladder” syndrome. Patients engage in maladaptive anticipatory processing (worrying for weeks before an event) and post-event rumination (obsessively reviewing flaws), which maintains the anxiety cycle. Subtypes include performance-only (public speaking) and generalised (most social situations). In collectivist cultures (Japan, Korea), fear may manifest as taijin kyofusho—worry that one’s appearance will offend others.
Therapeutic Interventions
First-line psychotherapy is Cognitive Behavioural Therapy (CBT) utilising exposure, cognitive restructuring, and social skills training, with a success rate of 60–70%. First-line pharmacotherapy includes SSRIs (sertraline, paroxetine, escitalopram). Beta-blockers (propranolol) are highly effective for performance-only anxiety when taken as needed. For treatment-resistant cases, repetitive transcranial magnetic stimulation (rTMS) represents an innovative option.
Social Anxiety Disorder is a highly treatable condition extending far beyond shyness, impairing quality of life, education, and independence if unaddressed. With targeted interventions—CBT, SSRIs, or neuromodulation—individuals can achieve substantial symptom reduction, reclaiming the autonomy and confidence to navigate social interactions without the tyrannical grip of anticipatory dread.
